Pharmaceutical

AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients

This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).

Oct 22, 2024 - 04:00
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients
This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).
Read the original article

Tags:

Previous Article

Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

Next Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

An effort to diversify genetic research finds new variant for Parkinson’s disease in African populations

An effort to diversify genetic research finds new varia...

Aug 25, 2023

Kate Cox is one of hundreds in Texas denied abortions despite serious health risks, data show

Kate Cox is one of hundreds in Texas denied abortions d...

Dec 15, 2023

Biden to tap head of National Cancer Institute to lead NIH

Biden to tap head of National Cancer Institute to lead NIH

Apr 21, 2023